Online inquiry

IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14238MR)

This product GTTS-WQ14238MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14238MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10298MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ3787MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ2386MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ328MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ15083MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ14475MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ4991MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ809MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW